Literature DB >> 7742068

Reconstruction of cortical bone remodeling in untreated primary hyperparathyroidism and following surgery.

H Brockstedt1, P Christiansen, L Mosekilde, F Melsen.   

Abstract

Iliac crest bone biopsies from 39 patients (23 women, 16 men) with untreated primary hyperparathyroidism (PHP) were examined. Static histomorphometric parameters for cortical bone was compared with values obtained from 39 age- and sex-matched normal controls. Thirty-five of the patients were double-labeled with tetracycline before biopsy. The cortical remodeling cycle was reconstructed in these patients and compared with 24 sex-matched but younger normal controls. In 9 patients, a second intact bone biopsy was obtained 6-12 months after successful surgery for PHP. In these patients, pre- and post-treatment biopsies were compared. Cortical porosity was increased in PHP (p < 0.001) due to a high turnover state with expansion of the remodeling space (p < 0.001). The net balance of the remodeling cycle on the haversian surface was found unchanged in PHP, since the average haversian canal diameter remained unchanged. In the female PHP-patients, a significant increase in the final resorption depth (p < 0.01) was balanced by a proportional increase in the wall width (p < 0.001). Among all PHP patients, no significant decrease in cortical width was found. However, a significant reduction in absolute (p < 0.05) and fractional cortical width (p < 0.05) was seen in postmenopausal PHP women giving rise to a cortical bone loss. Reconstruction of the cortical remodeling cycle revealed a doubling in activation frequency from 0.6#/year in normals to 1.2#/year in PHP (p < 0.001), giving rise to a high turnover state. Surgical cure of PHP was accompanied by marked changes in cortical bone metabolism.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7742068     DOI: 10.1016/s8756-3282(94)00017-4

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

1.  Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism.

Authors:  Emily M Stein; David W Dempster; Julia Udesky; Hua Zhou; John P Bilezikian; Elizabeth Shane; Shonni J Silverberg
Journal:  Bone       Date:  2010-10-13       Impact factor: 4.398

Review 2.  Parathyroid Hormone-Related Changes of Bone Structure.

Authors:  M Kužma; P Jackuliak; Z Killinger; J Payer
Journal:  Physiol Res       Date:  2021-11-30       Impact factor: 1.881

3.  Presentation and Outcomes After Surgery for Primary Hyperparathyroidism During an 18-Year Period.

Authors:  Mark Thier; Erik Nordenström; Anders Bergenfelz; Martin Almquist
Journal:  World J Surg       Date:  2016-02       Impact factor: 3.352

4.  Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.

Authors:  N E Lane; S Sanchez; G W Modin; H K Genant; E Pierini; C D Arnaud
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

5.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

Authors:  Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

6.  Innervation is higher above Bone Remodeling Surfaces and in Cortical Pores in Human Bone: Lessons from patients with primary hyperparathyroidism.

Authors:  Manasi Sayilekshmy; Rie Bager Hansen; Jean-Marie Delaissé; Lars Rolighed; Thomas Levin Andersen; Anne-Marie Heegaard
Journal:  Sci Rep       Date:  2019-03-29       Impact factor: 4.379

7.  Single-centre cross-sectional study on the impact of cumulative erythropoietin on bone mineral density in maintenance dialysis patients.

Authors:  Chung-Yi Cheng; Yi-Jie Kuo
Journal:  BMJ Open       Date:  2022-04-12       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.